Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC.

Clin Cancer Res. 2012 Sep 1;18(17):4570-9. doi: 10.1158/1078-0432.CCR-12-0550. Epub 2012 Aug 23.

2.

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.

Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, Engelman JA, Fujita N.

Clin Cancer Res. 2015 Jan 1;21(1):166-74. doi: 10.1158/1078-0432.CCR-14-1385. Epub 2014 Oct 28.

3.

CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma.

Matsuura S, Shinmura K, Kamo T, Igarashi H, Maruyama K, Tajima M, Ogawa H, Tanahashi M, Niwa H, Funai K, Kohno T, Suda T, Sugimura H.

Oncol Rep. 2013 Oct;30(4):1675-80. doi: 10.3892/or.2013.2630. Epub 2013 Jul 19.

PMID:
23877438
4.

Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency.

Inoue M, Toki H, Matsui J, Togashi Y, Dobashi A, Fukumura R, Gondo Y, Minowa O, Tanaka N, Mori S, Takeuchi K, Noda T.

Carcinogenesis. 2016 May;37(5):452-60. doi: 10.1093/carcin/bgw028. Epub 2016 Mar 10.

PMID:
26964870
5.

Activation of RAS family members confers resistance to ROS1 targeting drugs.

Cargnelutti M, Corso S, Pergolizzi M, Mévellec L, Aisner DL, Dziadziuszko R, Varella-Garcia M, Comoglio PM, Doebele RC, Vialard J, Giordano S.

Oncotarget. 2015 Mar 10;6(7):5182-94.

6.

[A new target in non-small cell lung cancer: ROS1 fusion gene].

Cai WJ, Su B.

Zhonghua Zhong Liu Za Zhi. 2013 Jan;35(1):1-4. doi: 10.3760/cma.j.issn.0253-3766.2013.01.001. Review. Chinese. No abstract available.

PMID:
23648291
7.

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.

Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA Jr, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC.

PLoS One. 2013 Dec 13;8(12):e82236. doi: 10.1371/journal.pone.0082236. eCollection 2013.

8.

Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations.

Chen YF, Hsieh MS, Wu SG, Chang YL, Shih JY, Liu YN, Tsai MF, Tsai TH, Yu CJ, Yang JC, Yang PC.

J Thorac Oncol. 2014 Aug;9(8):1171-9. doi: 10.1097/JTO.0000000000000232.

9.

Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.

Song A, Kim TM, Kim DW, Kim S, Keam B, Lee SH, Heo DS.

Clin Cancer Res. 2015 May 15;21(10):2379-87. doi: 10.1158/1078-0432.CCR-14-1350. Epub 2015 Feb 16.

10.

Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.

Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, Mack JS, Silver MR, Zhou X, Haack H.

Clin Cancer Res. 2012 Aug 15;18(16):4449-57. doi: 10.1158/1078-0432.CCR-11-3351. Epub 2012 Jun 1.

11.

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

Aisner DL, Nguyen TT, Paskulin DD, Le AT, Haney J, Schulte N, Chionh F, Hardingham J, Mariadason J, Tebbutt N, Doebele RC, Weickhardt AJ, Varella-Garcia M.

Mol Cancer Res. 2014 Jan;12(1):111-8. doi: 10.1158/1541-7786.MCR-13-0479-T. Epub 2013 Dec 2.

12.

ROS1 rearrangements define a unique molecular class of lung cancers.

Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ.

J Clin Oncol. 2012 Mar 10;30(8):863-70. doi: 10.1200/JCO.2011.35.6345. Epub 2012 Jan 3.

13.

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.

Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB.

J Thorac Oncol. 2012 Jul;7(7):1086-90. doi: 10.1097/JTO.0b013e3182570919.

14.

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.

Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bae MK, Ou SH, Wang J, Jewell SS, Kang DR, Soo RA, Haack H, Kim JH, Shim HS, Cho BC.

Ann Oncol. 2013 Sep;24(9):2364-70. doi: 10.1093/annonc/mdt220. Epub 2013 Jun 19.

PMID:
23788756
15.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ.

N Engl J Med. 2014 Nov 20;371(21):1963-71. doi: 10.1056/NEJMoa1406766. Epub 2014 Sep 27.

16.

A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer.

Wijesinghe P, Bepler G, Bollig-Fischer A.

J Thorac Oncol. 2015 Feb;10(2):381-6. doi: 10.1097/JTO.0000000000000337.

17.

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.

Dziadziuszko R, Le AT, Wrona A, Jassem J, Camidge DR, Varella-Garcia M, Aisner DL, Doebele RC.

J Thorac Oncol. 2016 Aug;11(8):1273-1281. doi: 10.1016/j.jtho.2016.04.001. Epub 2016 Apr 9.

18.

[Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].

Zhong S, Zhang H, Bai D, Gao D, Zheng J, Ding Y.

Zhonghua Bing Li Xue Za Zhi. 2015 Sep;44(9):639-43. Chinese.

PMID:
26705279
19.

ROS1 fusions in Chinese patients with non-small-cell lung cancer.

Cai W, Li X, Su C, Fan L, Zheng L, Fei K, Zhou C, Manegold C, Schmid-Bindert G.

Ann Oncol. 2013 Jul;24(7):1822-7. doi: 10.1093/annonc/mdt071. Epub 2013 Mar 20.

PMID:
23514723
20.

Molecular pathways: ROS1 fusion proteins in cancer.

Davies KD, Doebele RC.

Clin Cancer Res. 2013 Aug 1;19(15):4040-5. doi: 10.1158/1078-0432.CCR-12-2851. Epub 2013 May 29. Review.

Supplemental Content

Support Center